Orion Corp
KRX:271560

Watchlist Manager
Orion Corp Logo
Orion Corp
KRX:271560
Watchlist
Price: 103 800 KRW -0.19% Market Closed
Market Cap: 4.1T KRW

Orion Corp
Other Long-Term Assets

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Orion Corp
Other Long-Term Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Long-Term Assets CAGR 3Y CAGR 5Y CAGR 10Y
Orion Corp
KRX:271560
Other Long-Term Assets
â‚©27.7B
CAGR 3-Years
2%
CAGR 5-Years
5%
CAGR 10-Years
N/A
CJ CheilJedang Corp
KRX:097950
Other Long-Term Assets
â‚©404.8B
CAGR 3-Years
0%
CAGR 5-Years
4%
CAGR 10-Years
3%
Ottogi Corp
KRX:007310
Other Long-Term Assets
â‚©23.6B
CAGR 3-Years
-7%
CAGR 5-Years
29%
CAGR 10-Years
25%
S
Samyang Foods Co Ltd
KRX:003230
Other Long-Term Assets
â‚©33.3B
CAGR 3-Years
146%
CAGR 5-Years
68%
CAGR 10-Years
32%
Dongwon Industries Co Ltd
KRX:006040
Other Long-Term Assets
â‚©137.5B
CAGR 3-Years
48%
CAGR 5-Years
20%
CAGR 10-Years
17%
Nongshim Co Ltd
KRX:004370
Other Long-Term Assets
â‚©11.5B
CAGR 3-Years
-30%
CAGR 5-Years
-13%
CAGR 10-Years
41%
No Stocks Found

Orion Corp
Glance View

Market Cap
4.1T KRW
Industry
Food Products

Perched within the competitive landscape of pharmaceuticals, Orion Corporation has steadily carved its niche since its inception in Finland in 1917. Starting as a small-scale factory operation, Orion has evolved into a pivotal player in the healthcare sector, blending traditional expertise with cutting-edge innovations. The company's core operations pivot around the development, manufacturing, and marketing of human and veterinary pharmaceuticals, as well as active pharmaceutical ingredients (APIs). This dual focus allows Orion not only to reach a diverse market but also ensures a consistent revenue stream, supplemented by its strategic interest in self-care products. The company thrives on its robust research and development arm, constantly seeking innovations in therapeutic areas like central nervous system disorders, oncology, and respiratory diseases. Orion's financial engine hums efficiently through its vertically integrated business model. By managing most of the value chain internally—from drug discovery to production and distribution—Orion secures cost advantages and quality control, translating into a competitive edge in global markets. While Europe remains Orion's stronghold, it strategically seeks growth in regional markets, leveraging partnerships and alliances with international pharmaceutical giants to expand its footprint. This strategy not only augments its own pipeline with licensed products but also fortifies its market position, making it a sustainable player in an industry driven by constant change and regulated rigorously. The corporation's revenue streams thus embody a careful balance of organic product development and strategic collaborations, evidencing a business acumen grounded in long-term vision.

Intrinsic Value
147 455.41 KRW
Undervaluation 30%
Intrinsic Value
Price

See Also

What is Orion Corp's Other Long-Term Assets?
Other Long-Term Assets
27.7B KRW

Based on the financial report for Jun 30, 2025, Orion Corp's Other Long-Term Assets amounts to 27.7B KRW.

What is Orion Corp's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 5Y
5%

Over the last year, the Other Long-Term Assets growth was 15%. The average annual Other Long-Term Assets growth rates for Orion Corp have been 2% over the past three years , 5% over the past five years .

Back to Top